Our Impact

In a systematic review including nearly 25 million patients diagnosed with early-onset colorectal cancer (EOCRC), Joshua Demb, PhD, MPH, and colleagues identify some of the most common presenting signs and symptoms.

Red flag signs and symptoms for early-onset colorectal cancer (EOCRC) are often missed, leading to delays in diagnosis and treatment. In a recent JAMA Network Open article featured in the New York Times, physicians and scientists explore some of the most common signs and symptoms of EOCRC.

Coming soon.

Allison Rosen, Chair of the PREFACE Patient Advisory Council, and Dr. Holowatyj were invited to discuss the clinical and research impact of their scientist-survivor partnership with colleagues at Bayer during the April 2024 AACR Annual Meeting in San Diego. Allison and Dr. Holowatyj featured the PREFACE Study and their ongoing partnership with the PREFACE Patient Advisory Council.

Coming soon.

The Oncofertility Consortium is a network of medical specialists, scientists, and scholars dedicated to exploring the reproductive future of cancer survivors. In this webinar, Dr. Andreana Holowatyj discusses trends in early-onset colorectal cancer, how cancer therapies can differentially impact younger patients, and how the PREFACE study aims to address fertility concerns for these patients.

Hosted by the Colon Cancer Foundation, the 8th annual EAO-CRC Summit brought together clinicians, scientists, and young adult cancer survivors to discuss the unique needs of EAO-CRC patients as well as medical and research advancements. Serving as presenting faculty for this event, Dr. Andreana Holowatyj spoke on the disparities in early-age onset colorectal cancer.  

"In a groundbreaking collaboration, Fight CRC, Vanderbilt, and the National Cancer Institute have established a think tank dedicated to accelerating research on early-age onset colorectal cancer (EAO CRC). Located in the heart of Nashville, this think tank is more than just a gathering — it’s a powerful movement." The think tank aims to lay a foundation for future research to better understanding the biology and etiology of EAO CRC. 

In collaboration with Worth the Wait, Colontown, and Elephants and Tea, we discussed the impact of colorectal cancer on fertility as well as resources for patients.

The 2024 Vanderbilt Translational Research Forum celebrates the successes of translational research at Vanderbilt and provides a networking opportunity for students and investigators. As a plenary speaker, Dr. Andreana Holowatyj discusses reproductive health in the clinical management of early-onset colorectal cancer. 

"'As the number of adults within their childbearing years diagnosed with, treated for and surviving colorectal cancer continues to rise, reproductive health concerns remain an unmet need within this growing patient population. Funding from this NCI MERIT award directly supports our research that aims to close this gap and ultimately lead to incorporating reproductive health care into routine clinical management of early-onset colorectal cancer and to improve our patient outcomes,' Holowatyj said."

Dr. Shannon Westin and her guest, Dr. Andreana Holowatyj, discuss the paper "Clinical Multigene Panel Testing Identifies Racial and Ethnic Differences in Germline Pathogenic Variants Among Patients With Early-Onset Colorectal Cancer," recently published in JCO.

'"As the incidence rates of early-onset colorectal cancer continue to rise and yield a disproportionate impact across diverse populations, our findings draw timely attention to the need for health equity considerations in multi-gene panel testing development,' said the study's corresponding author, Andreana Holowatyj, Ph.D., MSCI, assistant professor of Medicine at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center."

"Germline genetic features differed by race/ethnicity in young patients with CRC, suggesting that current multigene panel tests may not be representative of EOCRC risk in diverse populations. Further study is needed to optimize genes selected for genetic testing in EOCRC via ancestry-specific gene and variant discovery to yield equitable clinical benefits for all patients and to mitigate inequities in disease burden." - Dr. Holowatyj and colleagues 

Understanding the biological underpinnings of early-onset colorectal cancer has been a major focus of Andreana N. Holowatyj, PhD, MS, assistant professor of medicine and cancer biology at the Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center. In a study published this month in AACR journal Cancer Discovery, Holowatyj and colleagues explained that while the cause of early-onset colorectal cancer is unknown, multiple factors likely contribute, including diet, social determinants of health, and genetics.

There were significant differences for LRP1B, FLT4, FBXW7, RNF43, ATRX, APC and PIK3CA mutation frequencies in early-onset non-hypermutated CRCs between racial/ethnic groups. Heterogeneities by race/ethnicity were observed for the effect of APC, FLT4 and FAT1 between early-onset and late-onset non-hypermutated CRC. By sex, heterogeneity was observed for the effect of EP300, BRAF, WRN, KRAS, AXIN2 and SMAD2. Males and females with non-hypermutated CRC had different trends in EP300 mutations by age group.

The entire colorectal cancer community was invited to tune into FightCRC's virtual international symposium on early-onset colorectal cancer in June 2022. In the Panel defining 'Novel and unique dimensions from early-onset CRC', Dr. Holowatyj presented on "Fertility and sexual health after early-onset colorectal cancer diagnosis and treatment: Results from the REACT Study".

The PREFACE Study is a proud member of the Oncofertility Consortium—an international, interdisciplinary initiative designed to explore the reproductive future of cancer survivors—since January 2022!

"Before initiating cancer therapy, candid and empathic discussions about fertility preservation cannot be overlooked in adults of child-bearing age." The PREFACE Study is also highlighted in this article by Eng and colleagues.

"Among young patients, there is a greater need to treat the whole patient for whom multiple life domains (eg, sexual health and fertility) are significantly affected by the [colorectal] cancer diagnosis." -Dr. Holowatyj and colleagues